HALIFAX, NS / ACCESSWIRE / / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended ...
The Nova Scotia-based firm's Multiplo Rapid TP/HIV Test is used to detect antibodies to HIV 1/2 and syphilis in a finger prick blood sample.
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, ...
Medmira (TSE:MIR) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street analysts, ...
During Q1 FY2025, MedMira has been continuing its regulatory work and clinical trials for its Reveal® G4 HIV-1/2 rapid test CLIA-waiver and with it made substantial progress on its FDA ...
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback